Buprenorphine Program Evaluation in a Private Psychiatric Office-Based Practice

Area of Science:

• Addiction Medicine
• Psychiatry
• Public Health

Background:

• The opioid crisis significantly impacts mortality, morbidity, and healthcare costs in the U.S.
• Buprenorphine (BUP) is a key medication for treating opioid use disorder.
• Quality assurance is vital for optimizing BUP treatment programs.

Purpose of the Study:

• To evaluate a BUP program's effectiveness in achieving illicit opioid abstinence.
• To identify patient risk and resilience factors influencing recovery outcomes.
• To inform improvements for enhanced patient success in BUP treatment.

Main Methods:

• Retrospective chart review of open and closed cases (n=56).
• Cross-sectional survey of open cases assessing risk and resilience.
• Analysis of opioid-negative urine tests and completed monthly urine drug tests (UDTs).

Main Results:

• Open cases showed significantly higher opioid abstinence rates (88.57%) than closed cases (74.82%).
• Mandatory monthly UDTs stabilized case management.
• Most patients reported therapy engagement, low cravings, and using distraction for pain-related triggers.

Conclusions:

• The evaluated clinic achieved benchmarks for improved substance recovery.
• Regular monitoring of UDT, cravings, and pain is recommended.
• Continuous quality assurance and therapy participation are crucial for sustained recovery.